epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-512, Phase III. Recruitment complete
Moderate to severe ulcerative colitis
WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.
Where EPI-512 stands on September 30th 2026
Randomised471of 471 needed
Sites open70of 70 planned
Median forecast finishDoneDeadline Sep 2024
FinishCompleteRecruitment reached its target.Open the plan
Enrolment94% of planRandomised to date against the count the plan expected by now.Open KPIs
Sites40 of 70 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
KRIs31 of 70 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
QTLsAll 4 withinStudy-level quality limits, judged once enough patients are in.Open QTLs